Study flowchart. Outcome of patients with a history of iTTP who received a first course of preemptive rituximab (ADAMTS13 activity <10% during follow-up) (A). Patients who experienced a persistent severe ADAMTS13 deficiency following the first course of preemptive rituximab are detailed (B). Patients who relapsed are denoted by £ and *.